192 related articles for article (PubMed ID: 12801603)
1. Dietary glycotoxins promote diabetic atherosclerosis in apolipoprotein E-deficient mice.
Lin RY; Choudhury RP; Cai W; Lu M; Fallon JT; Fisher EA; Vlassara H
Atherosclerosis; 2003 Jun; 168(2):213-20. PubMed ID: 12801603
[TBL] [Abstract][Full Text] [Related]
2. Advanced glycation end product interventions reduce diabetes-accelerated atherosclerosis.
Forbes JM; Yee LT; Thallas V; Lassila M; Candido R; Jandeleit-Dahm KA; Thomas MC; Burns WC; Deemer EK; Thorpe SR; Cooper ME; Allen TJ
Diabetes; 2004 Jul; 53(7):1813-23. PubMed ID: 15220206
[TBL] [Abstract][Full Text] [Related]
3. Lack of the antioxidant enzyme glutathione peroxidase-1 accelerates atherosclerosis in diabetic apolipoprotein E-deficient mice.
Lewis P; Stefanovic N; Pete J; Calkin AC; Giunti S; Thallas-Bonke V; Jandeleit-Dahm KA; Allen TJ; Kola I; Cooper ME; de Haan JB
Circulation; 2007 Apr; 115(16):2178-87. PubMed ID: 17420349
[TBL] [Abstract][Full Text] [Related]
4. Advanced glycation endproducts promote adhesion molecule (VCAM-1, ICAM-1) expression and atheroma formation in normal rabbits.
Vlassara H; Fuh H; Donnelly T; Cybulsky M
Mol Med; 1995 May; 1(4):447-56. PubMed ID: 8521302
[TBL] [Abstract][Full Text] [Related]
5. Advanced glycation end-product Nε-carboxymethyl-Lysine accelerates progression of atherosclerotic calcification in diabetes.
Wang Z; Jiang Y; Liu N; Ren L; Zhu Y; An Y; Chen D
Atherosclerosis; 2012 Apr; 221(2):387-96. PubMed ID: 22305260
[TBL] [Abstract][Full Text] [Related]
6. Glucagon-like peptide-1 analogue liraglutide ameliorates atherogenesis via inhibiting advanced glycation end product-induced receptor for advanced glycosylation end product expression in apolipoprotein-E deficient mice.
Li P; Tang Z; Wang L; Feng B
Mol Med Rep; 2017 Sep; 16(3):3421-3426. PubMed ID: 28713911
[TBL] [Abstract][Full Text] [Related]
7. Supplementation of cyanidin-3-O-β-glucoside promotes endothelial repair and prevents enhanced atherogenesis in diabetic apolipoprotein E-deficient mice.
Zhang Y; Wang X; Wang Y; Liu Y; Xia M
J Nutr; 2013 Aug; 143(8):1248-53. PubMed ID: 23761653
[TBL] [Abstract][Full Text] [Related]
8. Prevention of accelerated atherosclerosis by angiotensin-converting enzyme inhibition in diabetic apolipoprotein E-deficient mice.
Candido R; Jandeleit-Dahm KA; Cao Z; Nesteroff SP; Burns WC; Twigg SM; Dilley RJ; Cooper ME; Allen TJ
Circulation; 2002 Jul; 106(2):246-53. PubMed ID: 12105166
[TBL] [Abstract][Full Text] [Related]
9. Protection from diabetes-induced atherosclerosis and renal disease by D-carnosine-octylester: effects of early vs late inhibition of advanced glycation end-products in Apoe-null mice.
Menini S; Iacobini C; Ricci C; Blasetti Fantauzzi C; Pugliese G
Diabetologia; 2015 Apr; 58(4):845-53. PubMed ID: 25471794
[TBL] [Abstract][Full Text] [Related]
10. A 1,3-diacylglycerol-rich oil induces less atherosclerosis and lowers plasma cholesterol in diabetic apoE-deficient mice.
Fujii A; Allen TJ; Nestel PJ
Atherosclerosis; 2007 Jul; 193(1):55-61. PubMed ID: 16996521
[TBL] [Abstract][Full Text] [Related]
11. Immunization with advanced glycation end products modified low density lipoprotein inhibits atherosclerosis progression in diabetic apoE and LDLR null mice.
Zhu L; He Z; Wu F; Ding R; Jiang Q; Zhang J; Fan M; Wang X; Eva B; Jan N; Liang C; Wu Z
Cardiovasc Diabetol; 2014 Nov; 13():151. PubMed ID: 25391642
[TBL] [Abstract][Full Text] [Related]
12. Iron-deficient diet reduces atherosclerotic lesions in apoE-deficient mice.
Lee TS; Shiao MS; Pan CC; Chau LY
Circulation; 1999 Mar; 99(9):1222-9. PubMed ID: 10069791
[TBL] [Abstract][Full Text] [Related]
13. Effect of macrophage-derived apolipoprotein E on hyperlipidemia and atherosclerosis of LDLR-deficient mice.
Shi W; Wang X; Wong J; Hedrick CC; Wong H; Castellani LW; Lusis AJ
Biochem Biophys Res Commun; 2004 Apr; 317(1):223-9. PubMed ID: 15047172
[TBL] [Abstract][Full Text] [Related]
14. Lowering of dietary advanced glycation endproducts (AGE) reduces neointimal formation after arterial injury in genetically hypercholesterolemic mice.
Lin RY; Reis ED; Dore AT; Lu M; Ghodsi N; Fallon JT; Fisher EA; Vlassara H
Atherosclerosis; 2002 Aug; 163(2):303-11. PubMed ID: 12052477
[TBL] [Abstract][Full Text] [Related]
15. Effect of streptozotocin-induced hyperglycemia on lipid profiles, formation of advanced glycation endproducts in lesions, and extent of atherosclerosis in LDL receptor-deficient mice.
Reaven P; Merat S; Casanada F; Sutphin M; Palinski W
Arterioscler Thromb Vasc Biol; 1997 Oct; 17(10):2250-6. PubMed ID: 9351397
[TBL] [Abstract][Full Text] [Related]
16. Increased atherosclerosis in streptozotocin-induced diabetic mice.
Kunjathoor VV; Wilson DL; LeBoeuf RC
J Clin Invest; 1996 Apr; 97(7):1767-73. PubMed ID: 8601643
[TBL] [Abstract][Full Text] [Related]
17. Atorvastatin has hypolipidemic and anti-inflammatory effects in apoE/LDL receptor-double-knockout mice.
Nachtigal P; Pospisilova N; Jamborova G; Pospechova K; Solichova D; Andrys C; Zdansky P; Micuda S; Semecky V
Life Sci; 2008 Mar; 82(13-14):708-17. PubMed ID: 18289605
[TBL] [Abstract][Full Text] [Related]
18. Supplementation of diets with the black rice pigment fraction attenuates atherosclerotic plaque formation in apolipoprotein e deficient mice.
Xia M; Ling WH; Ma J; Kitts DD; Zawistowski J
J Nutr; 2003 Mar; 133(3):744-51. PubMed ID: 12612147
[TBL] [Abstract][Full Text] [Related]
19. ICAM-1 deficiency reduces atherosclerotic lesions in double-knockout mice (ApoE(-/-)/ICAM-1(-/-)) fed a fat or a chow diet.
Bourdillon MC; Poston RN; Covacho C; Chignier E; Bricca G; McGregor JL
Arterioscler Thromb Vasc Biol; 2000 Dec; 20(12):2630-5. PubMed ID: 11116064
[TBL] [Abstract][Full Text] [Related]
20. Rosiglitazone (PPARgamma-agonist) attenuates atherogenesis with no effect on hyperglycaemia in a combined diabetes-atherosclerosis mouse model.
Levi Z; Shaish A; Yacov N; Levkovitz H; Trestman S; Gerber Y; Cohen H; Dvir A; Rhachmani R; Ravid M; Harats D
Diabetes Obes Metab; 2003 Jan; 5(1):45-50. PubMed ID: 12542724
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
